Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review
Increasing evidence suggests that the gut microbiome is associated with both cancer chemotherapy (CTX) outcomes and adverse events (AEs). This review examines the relationship between the gut microbiome and CTX as well as the impact of CTX on the gut microbiome. A literature search was conducted in...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.706331/full |
id |
doaj-55fe88a7821b4413912e926930a2d51c |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Byeongsang Oh Byeongsang Oh Byeongsang Oh Byeongsang Oh Frances Boyle Frances Boyle Nick Pavlakis Nick Pavlakis Stephen Clarke Stephen Clarke Alex Guminski Alex Guminski Alex Guminski Thomas Eade Thomas Eade Thomas Eade Gillian Lamoury Gillian Lamoury Gillian Lamoury Susan Carroll Susan Carroll Susan Carroll Marita Morgia Marita Morgia Andrew Kneebone Andrew Kneebone Andrew Kneebone George Hruby George Hruby George Hruby Mark Stevens Mark Stevens Wen Liu Brian Corless Mark Molloy Towia Libermann Towia Libermann David Rosenthal Michael Back Michael Back Michael Back |
spellingShingle |
Byeongsang Oh Byeongsang Oh Byeongsang Oh Byeongsang Oh Frances Boyle Frances Boyle Nick Pavlakis Nick Pavlakis Stephen Clarke Stephen Clarke Alex Guminski Alex Guminski Alex Guminski Thomas Eade Thomas Eade Thomas Eade Gillian Lamoury Gillian Lamoury Gillian Lamoury Susan Carroll Susan Carroll Susan Carroll Marita Morgia Marita Morgia Andrew Kneebone Andrew Kneebone Andrew Kneebone George Hruby George Hruby George Hruby Mark Stevens Mark Stevens Wen Liu Brian Corless Mark Molloy Towia Libermann Towia Libermann David Rosenthal Michael Back Michael Back Michael Back Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review Frontiers in Oncology gut microbiome chemotherapy cancer biomarker adverse events |
author_facet |
Byeongsang Oh Byeongsang Oh Byeongsang Oh Byeongsang Oh Frances Boyle Frances Boyle Nick Pavlakis Nick Pavlakis Stephen Clarke Stephen Clarke Alex Guminski Alex Guminski Alex Guminski Thomas Eade Thomas Eade Thomas Eade Gillian Lamoury Gillian Lamoury Gillian Lamoury Susan Carroll Susan Carroll Susan Carroll Marita Morgia Marita Morgia Andrew Kneebone Andrew Kneebone Andrew Kneebone George Hruby George Hruby George Hruby Mark Stevens Mark Stevens Wen Liu Brian Corless Mark Molloy Towia Libermann Towia Libermann David Rosenthal Michael Back Michael Back Michael Back |
author_sort |
Byeongsang Oh |
title |
Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review |
title_short |
Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review |
title_full |
Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review |
title_fullStr |
Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review |
title_full_unstemmed |
Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review |
title_sort |
emerging evidence of the gut microbiome in chemotherapy: a clinical review |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-09-01 |
description |
Increasing evidence suggests that the gut microbiome is associated with both cancer chemotherapy (CTX) outcomes and adverse events (AEs). This review examines the relationship between the gut microbiome and CTX as well as the impact of CTX on the gut microbiome. A literature search was conducted in electronic databases Medline, PubMed and ScienceDirect, with searches for “cancer” and “chemotherapy” and “microbiome/microbiota”. The relevant literature was selected for use in this article. Seventeen studies were selected on participants with colorectal cancer (CRC; n=5), Acute Myeloid Leukemia (AML; n=3), Non-Hodgkin’s lymphoma (n=2), breast cancer (BCa; n=1), lung cancer (n=1), ovarian cancer (n=1), liver cancer (n=1), and various other types of cancers (n=3). Seven studies assessed the relationship between the gut microbiome and CTX with faecal samples collected prior to (n=3) and following CTX (n=4) showing that the gut microbiome is associated with both CTX efficacy and toxicity. Ten other prospective studies assessed the impact of CTX during treatment and found that CTX modulates the gut microbiome of people with cancer and that dysbiosis induced by the CTX is related to AEs. CTX adversely impacts the gut microbiome, inducing dysbiosis and is associated with CTX outcomes and AEs. Current evidence provides insights into the gut microbiome for clinicians, cancer survivors and the general public. More research is required to better understand and modify the impact of CTX on the gut microbiome. |
topic |
gut microbiome chemotherapy cancer biomarker adverse events |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.706331/full |
work_keys_str_mv |
AT byeongsangoh emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT byeongsangoh emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT byeongsangoh emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT byeongsangoh emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT francesboyle emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT francesboyle emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT nickpavlakis emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT nickpavlakis emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT stephenclarke emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT stephenclarke emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT alexguminski emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT alexguminski emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT alexguminski emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT thomaseade emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT thomaseade emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT thomaseade emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT gillianlamoury emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT gillianlamoury emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT gillianlamoury emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT susancarroll emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT susancarroll emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT susancarroll emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT maritamorgia emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT maritamorgia emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT andrewkneebone emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT andrewkneebone emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT andrewkneebone emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT georgehruby emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT georgehruby emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT georgehruby emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT markstevens emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT markstevens emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT wenliu emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT briancorless emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT markmolloy emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT towialibermann emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT towialibermann emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT davidrosenthal emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT michaelback emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT michaelback emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview AT michaelback emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview |
_version_ |
1717378392162041856 |
spelling |
doaj-55fe88a7821b4413912e926930a2d51c2021-09-16T04:37:53ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.706331706331Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical ReviewByeongsang Oh0Byeongsang Oh1Byeongsang Oh2Byeongsang Oh3Frances Boyle4Frances Boyle5Nick Pavlakis6Nick Pavlakis7Stephen Clarke8Stephen Clarke9Alex Guminski10Alex Guminski11Alex Guminski12Thomas Eade13Thomas Eade14Thomas Eade15Gillian Lamoury16Gillian Lamoury17Gillian Lamoury18Susan Carroll19Susan Carroll20Susan Carroll21Marita Morgia22Marita Morgia23Andrew Kneebone24Andrew Kneebone25Andrew Kneebone26George Hruby27George Hruby28George Hruby29Mark Stevens30Mark Stevens31Wen Liu32Brian Corless33Mark Molloy34Towia Libermann35Towia Libermann36David Rosenthal37Michael Back38Michael Back39Michael Back40Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaUniversity of Kansas Medical Center, Kansas City, KS, United StatesCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaUniversity of Kansas Medical Center, Kansas City, KS, United StatesNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaBowel Cancer and Biomarker Laboratory, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaBeth Israel Deaconess Medical Center (BIDMC) Genomics, Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center, Boston, MA, United StatesHarvard Medical School, Boston, MA, United StatesHarvard Medical School, Boston, MA, United StatesNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaIncreasing evidence suggests that the gut microbiome is associated with both cancer chemotherapy (CTX) outcomes and adverse events (AEs). This review examines the relationship between the gut microbiome and CTX as well as the impact of CTX on the gut microbiome. A literature search was conducted in electronic databases Medline, PubMed and ScienceDirect, with searches for “cancer” and “chemotherapy” and “microbiome/microbiota”. The relevant literature was selected for use in this article. Seventeen studies were selected on participants with colorectal cancer (CRC; n=5), Acute Myeloid Leukemia (AML; n=3), Non-Hodgkin’s lymphoma (n=2), breast cancer (BCa; n=1), lung cancer (n=1), ovarian cancer (n=1), liver cancer (n=1), and various other types of cancers (n=3). Seven studies assessed the relationship between the gut microbiome and CTX with faecal samples collected prior to (n=3) and following CTX (n=4) showing that the gut microbiome is associated with both CTX efficacy and toxicity. Ten other prospective studies assessed the impact of CTX during treatment and found that CTX modulates the gut microbiome of people with cancer and that dysbiosis induced by the CTX is related to AEs. CTX adversely impacts the gut microbiome, inducing dysbiosis and is associated with CTX outcomes and AEs. Current evidence provides insights into the gut microbiome for clinicians, cancer survivors and the general public. More research is required to better understand and modify the impact of CTX on the gut microbiome.https://www.frontiersin.org/articles/10.3389/fonc.2021.706331/fullgut microbiomechemotherapycancerbiomarkeradverse events |